Chordia Therapeutics Inc. (TYO:190A)

Japan flag Japan · Delayed Price · Currency is JPY
129.00
+5.00 (4.03%)
Mar 10, 2026, 1:04 PM JST
Market Cap9.04B -49.8%
Revenue (ttm)n/a
Net Income-1.46B
EPS-21.22
Shares Out72.93M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume836,800
Average Volume4,084,045
Open126.00
Previous Close124.00
Day's Range125.00 - 131.00
52-Week Range98.00 - 284.00
Betan/a
RSI51.90
Earnings DateApr 10, 2026

About Chordia Therapeutics

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2017
Employees 23
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 190A
Full Company Profile

Financial Performance

Financial Statements